These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 15099807

  • 1. IL-1 beta, IL-1 receptor antagonist and soluble type II IL-1 receptor in synovial fluid of patients with temporomandibular disorders.
    Tominaga K, Habu M, Sukedai M, Hirota Y, Takahashi T, Fukuda J.
    Arch Oral Biol; 2004 Jun; 49(6):493-9. PubMed ID: 15099807
    [Abstract] [Full Text] [Related]

  • 2. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids.
    Arend WP, Malyak M, Smith MF, Whisenand TD, Slack JL, Sims JE, Giri JG, Dower SK.
    J Immunol; 1994 Nov 15; 153(10):4766-74. PubMed ID: 7963543
    [Abstract] [Full Text] [Related]

  • 3. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
    Kaneyama K, Segami N, Sun W, Sato J, Fujimura K.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar 15; 99(3):276-84. PubMed ID: 15716832
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-1beta, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides.
    Alstergren P, Benavente C, Kopp S.
    J Oral Maxillofac Surg; 2003 Oct 15; 61(10):1171-8. PubMed ID: 14586853
    [Abstract] [Full Text] [Related]

  • 5. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction.
    Jouvenne P, Vannier E, Dinarello CA, Miossec P.
    Arthritis Rheum; 1998 Jun 15; 41(6):1083-9. PubMed ID: 9627018
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma.
    Ricote M, García-Tuñón I, Bethencourt FR, Fraile B, Paniagua R, Royuela M.
    Cancer; 2004 Apr 01; 100(7):1388-96. PubMed ID: 15042672
    [Abstract] [Full Text] [Related]

  • 7. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
    Smeets RL, Joosten LA, Arntz OJ, Bennink MB, Takahashi N, Carlsen H, Martin MU, van den Berg WB, van de Loo FA.
    Arthritis Rheum; 2005 Jul 01; 52(7):2202-11. PubMed ID: 15986350
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis.
    Kopp S, Alstergren P, Ernestam S, Nordahl S, Bratt J.
    Scand J Rheumatol; 2006 Jul 01; 35(3):182-8. PubMed ID: 16766364
    [Abstract] [Full Text] [Related]

  • 9. [Role of interleukin-18, interleukin-1beta and its soluble receptor (sIL-1RII) in early and late Lyme borreliosis].
    Pietruczuk A, Swierzbińska R, Pietruczuk M, Hermanowska-Szpakowicz T.
    Pol Merkur Lekarski; 2004 Nov 01; 17(101):446-50. PubMed ID: 15754629
    [Abstract] [Full Text] [Related]

  • 10. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.
    Chabaud M, Miossec P.
    Arthritis Rheum; 2001 Jun 01; 44(6):1293-303. PubMed ID: 11407688
    [Abstract] [Full Text] [Related]

  • 11. Determination of interleukin-1 receptor antagonist, interleukin-10, and transforming growth factor-beta1 in synovial fluid aspirates of patients with temporomandibular disorders.
    Fang PK, Ma XC, Ma DL, Fu KY.
    J Oral Maxillofac Surg; 1999 Aug 01; 57(8):922-8; discussion 928-9. PubMed ID: 10437719
    [Abstract] [Full Text] [Related]

  • 12. Importance of proinflammatory cytokines in synovial fluid from 121 joints with temporomandibular disorders.
    Kaneyama K, Segami N, Nishimura M, Suzuki T, Sato J.
    Br J Oral Maxillofac Surg; 2002 Oct 01; 40(5):418-23. PubMed ID: 12379189
    [Abstract] [Full Text] [Related]

  • 13. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy.
    Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojsavljevic N, Nicoletti F, Drulovic J.
    J Neuroimmunol; 2009 Feb 15; 207(1-2):101-6. PubMed ID: 19162335
    [Abstract] [Full Text] [Related]

  • 14. Serum levels of interleukin-18 (IL-18), interleukin-1beta (IL-1beta), its soluble receptor sIL-1RII and C-reactive protein (CRP) in patients with Lyme arthritis.
    Pietruczuk A, Swierzbińska R, Pancewicz S, Pietruczuk M, Hermanowska-Szpakowicz T.
    Infection; 2006 Jun 15; 34(3):158-62. PubMed ID: 16804660
    [Abstract] [Full Text] [Related]

  • 15. Levels of soluble cytokine factors in temporomandibular joint effusions seen on magnetic resonance images.
    Kaneyama K, Segami N, Sun W, Sato J, Fujimura K.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Apr 15; 99(4):411-8. PubMed ID: 15772591
    [Abstract] [Full Text] [Related]

  • 16. [Concentration of interleukin-18, interleukin-1beta, soluble receptor for interleukin-1 (sIL-1RII) and C-reactive protein in patients with neuroborreliosis].
    Pietruczuk A, Swierzbińska R, Pietruczuk M, Kondrusik M, Zajkowska J, Pancewicz S, Hermanowska-Szpakowicz T.
    Neurol Neurochir Pol; 2005 Apr 15; 39(1):33-9. PubMed ID: 15735988
    [Abstract] [Full Text] [Related]

  • 17. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients.
    Sirota P, Meiman M, Herschko R, Bessler H.
    Psychiatry Res; 2005 Apr 15; 134(2):151-9. PubMed ID: 15840416
    [Abstract] [Full Text] [Related]

  • 18. Increased soluble interleukin-1 receptor type II proteolysis in the endometrium of women with endometriosis.
    Bellehumeur C, Collette T, Maheux R, Mailloux J, Villeneuve M, Akoum A.
    Hum Reprod; 2005 May 15; 20(5):1177-84. PubMed ID: 15705625
    [Abstract] [Full Text] [Related]

  • 19. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, Netter P, Jouzeau JY, Terlain B.
    Arthritis Rheum; 2005 Mar 15; 52(3):759-69. PubMed ID: 15751073
    [Abstract] [Full Text] [Related]

  • 20. Mapping of receptor binding sites on IL-1 beta by reconstruction of IL-1ra-like domains.
    Boraschi D, Bossù P, Ruggiero P, Tagliabue A, Bertini R, Macchia G, Gasbarro C, Pellegrini L, Melillo G, Ulisse E, Visconti U, Bizzarri C, Del Grosso E, Mackay AR, Frascotti G, Frigerio F, Grifantini R, Grandi G.
    J Immunol; 1995 Nov 15; 155(10):4719-25. PubMed ID: 7594472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.